Skip to main content
NCBI home page
PLOS One logoLink to PLOS One
. 2022 Apr 21;17(4):e0267139. doi: 10.1371/journal.pone.0267139

“Outcomes of COVID-19 infection in patients with hematological malignancies- A multicenter analysis from Pakistan”

Adeeba Zaki 1,2,*, Salman Muhammad Soomar 1,2, Danish Hasan Khan 3,4, Hasan Shaharyar Sheikh 5,6, Raheel Iftikhar 7, Ayaz Mir 8,9, Zeba Aziz 10,11, Khadija Bano 8,12, Hafsa Naseer 10,13, Qamar un–Nisa Chaudhry 7, Syed Waqas Imam Bokhari 5,14, Munira Shabbir-Moosajee 1,2
Editor: Sinan Kardeş15
PMCID: PMC9022796  PMID: 35446898

Abstract

Purpose

COVID-19 infection resulting from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began to spread across the globe in early 2020. Patients with hematologic malignancies are supposed to have an increased risk of mortality from coronavirus disease of 2019 (COVID-19) infection. From Pakistan, we report the analysis of the outcome and interaction between patient demographics and tumor subtype and COVID-19 infection and hematological malignancy.

Patients and methods

This multicenter, retrospective study included adult patients with a history of histologically proven hematological malignancies who were tested positive for COVID-19 via PCR presented at the oncology department of 5 tertiary care hospitals in Pakistan from February to August 2020. A patient with any known hematological malignancy who was positive for COVID-19 on RT-PCR, was included in the study. Chi-square test and Cox-regression hazard regression model was applied considering p ≤ 0.05 significant.

Results

A total of 107 patients with hematological malignancies were diagnosed with COVID-19, out of which 82 (76.64%) were alive, and 25 (23.36%) were dead. The significant hematological malignancy was B-cell Lymphoma in dead 4 (16.00%) and alive group 21 (25.61%), respectively. The majority of the patients in both the dead and alive group were on active treatment for hematological malignancy while they came positive for COVID-19 [21 (84.00%) & 48 (58.54%) p 0.020]. All patients in the dead group were admitted to the hospital 25 (100.00%), and among these, 14 (56.00%) were admitted in ICU with a median 11 (6–16.5) number of days. Among those who had contact exposure, the hazard of survival or death in patients with hematological malignancies and COVID-19 positive was 2.18 (CI: 1.90–4.44) times and 3.10 (CI: 2.73–4.60) times in patients with travel history compared to no exposure history (p 0.001).

Conclusion

Taken together, this data supports the emerging consensus that patients with hematologic malignancies experience significant morbidity and mortality resulting from COVID-19 infection.

Introduction

The SARS-Cov-2 or COVID-19, known as novel coronavirus, has become a global threat and healthcare concern. Since its outbreak in China at the end of 2019, the pandemic has affected more than 100 million people worldwide [1]. Although the outbreak is likely to have started from a zoonotic spread, it soon became apparent that person-to-person transmission occurs mainly through respiratory droplets and direct contact with a diseased person or indirect contact with fomites in the environment [2, 3]. Many people have mild symptoms. In contrast, others have no symptoms at all but still, actively carry and transmit the virus. However, some do develop severe symptoms such as respiratory failure, cytokine release syndrome, and multi-organ failure [4].

Since COVID-19 began to spread across the globe in early 2020, patients with comorbidities and cancer are more susceptible to marked complications of viral infection. Cancer patients are more prone to increased risk of infections than individuals without cancer because of immunosuppression by the malignancy itself and anticancer treatments, such as chemotherapy or surgery [5, 6] and have a poorer prognosis. Cao et al. have reported that patients with metastatic disease, hematological malignancy, or lung cancer are at particularly high risk of severe complications, requiring intensive care unit (ICU) admission, invasive mechanical ventilation, and even death. Furthermore, active treatment such as surgery and immunotherapy is associated with a significantly increased risk (hazard ratios of 6.22 and 4.82) respectively, for poor outcomes [7], Zhang et al. reported a higher rate of adverse events (53.6%) and mortality (28.6%) in those who had their last anti-tumor treatment within 14 days of the infection (HR = 4.079, 95% CI 1.086–15.322, P = 0.037). We do know that patients with hematological malignancies can have an underlying immune dysfunction and are vulnerable to viral and other infections [9]. Additionally, treatments which include cytotoxic agents, immunomodulators, hematopoietic stem cell transplantation, and chimeric antigen receptor T-cell therapy, are profoundly immunosuppressive. In addition, patients with hematologic malignancies have multiple risk factors of particular concern in the context of COVID-19 infection such as advanced age, underlying or treatment-induced comorbid illnesses like hypertension and diabetes, and chronic lymphopenia. These factors make this patient population particularly susceptible to an adverse outcome.

Public health measures are universally instituted to control the disease spread and aim to decrease preventable hospital admissions. In addition, it is recommended that patients receiving anticancer treatment should have vigorous screening for COVID-19 [8]. However, cancer care encompasses a diverse array of primary tumor types and stages, affecting all age groups of patients, with different prognosis and outcomes. Therefore, labeling all patients with cancer as susceptible to COVID-19 is probably neither reasonable nor informative.

For patients with hematologic malignancies, the overall risk of morbidity and mortality resulting from COVID-19 infection, as well as how this risk varies as a function of age, disease status, type of malignancy, and cancer therapy is being studied [9]. However, data from low- and middle-income countries is sparse. It is hypothesized that lower rates of testing and contact tracing and dearth of medical facilities adequately equipped to manage complicated covid infections can potentially result in higher morbidity and mortality in this high-risk population.

From Pakistan, we report the analysis of the interaction between patient demographics and tumor subtype and COVID-19 infection and outcomes in patients with hematological malignancy. This is a multicenter analysis from five tertiary care hospitals in Pakistan, all of whom have an established cancer center.

Materials and methods

We retrospectively collected data on all the patients with a history of histologically proven hematological malignancies that tested positive for COVID-19 by RT-PCR and present at the oncology department of 5 tertiary care hospitals in Pakistan: Aga Khan University Hospital Karachi, Armed Forces Bone Marrow Transplant Centre Rawalpindi, Hameed Latif Hospital Lahore, Shifa International Hospital Islamabad, and Shaukat Khanum Memorial Cancer Hospital Lahore from February to August 2020. Data was collected using a standard Performa developed for this study. Demographic, clinical, treatment, and laboratory data and serial samples for viral RNA detection were extracted from the medical records of 107 patients.

Patient with any known hematological malignancy who was positive for COVID-1f on RT-PCR was included in the study. Patients with a clinical or radiological diagnosis of COVID-19 without a positive RT-PCR test, were not included in this analysis.

Operational definition

Leukemia is cancer of the body’s blood-forming tissues, including the bone marrow and the lymphatic system [10].

Lymphoma is a cancer of the lymphatic system, which is part of the body’s germ-fighting network. The lymphatic system includes the lymph nodes (lymph glands), spleen, thymus gland, and bone marrow [11].

Multiple myeloma is a cancer of plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system [12].

Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow become abnormal. This leads to low numbers of one or more types of blood cells [12].

Clinical classification of suspected or confirmed COVID-19 patients in Pakistan

Asymptomatic SARS CoV-2 infection but with no symptoms. Some asymptomatic patients may be pre-symptomatic if tested early (e.g., as part of contact tracing) [13].

Non-Severe Oxygen saturation of 94% or greater and respiratory rate of less than 25 breaths/minute [14].

Severe Oxygen saturation < 94% and respiratory rate greater than 25 breaths/minute.

Oxygen saturation is maintained by nasal cannulation or simple facemask, no need for non-invasive or invasive mechanical ventilation [14].

Critical Respiratory compromise severe enough requiring invasive and non-invasive mechanical ventilation [13].

Variables

Age, Sex, Hospital, Co-morbidities, Hematological malignancy, treatment, chemotherapy, COVID-19 exposure, presenting complaint, hospital admission, COVID-19 status at death or discharge were the covariates.

Outcome

Mortality—the number of deaths in patients with hematological malignancy diagnosed with COVID-19 infection.

Statistical analysis

The data was entered and analyzed by using STATA version 16. Calculated medians for all continuous skewed variables. The normality of data was checked through density plots—frequencies with percentages for categorical variables. A Chi-square test was performed to check the association between the covariates and mortality. For survival analysis, a multivariable Cox-regression hazard regression model was applied, and the Kaplan Meir survival curve was used to check the overall survival. P-value ≤0.05 was considered significant.

Ethical approval

Ethical approval was obtained from the Ethical Review Committee of the Aga Khan University Hospital, Karachi, Pakistan. Data were retrospectively collected through chart review, so there was no need for the informed written consent.

Results

Baseline characteristics

A total of 107 patients with hematological malignancies were diagnosed with COVID-19, out of which 82 (76.64%) were alive, and 25 (23.36%) were dead. Among the dead, 12 (48.00%) of the participants were greater than 50 years of age (p 0.027). Most of the participants were males in both the dead and alive group [18 (72.00%) & 54 (68.85%)]. Hypertension was the common comorbidity in both groups [8 (32.00%) & 8 (9.76%) p 0.021]. The significant hematological malignancy was B-cell Lymphoma in dead 4 (16.00%) and alive group 21 (25.61%), respectively (Table 1). The majority of the patients in both the dead and alive group were on active treatment for hematological malignancy while they came positive for COVID-19 [21 (84.00%) & 48 (58.54%) p 0.020]. IV chemotherapy was the common treatment 15 (71.43%) from the dead group, and 29 (61.70%) in the alive group received IV chemotherapy moreover Idarubicin + cytarabine was the common IV chemo-regimen given to patients in both groups [5 (23.81%) & 5 (12.20%)] (Table 2). The presenting complaint in patients with hematological malignancies who catch COVID-19 among the dead group were fever (52.00%) followed by respiratory symptoms 11 (44.00%). However, in the alive group, 18 (21.95%) were asymptomatic, 22 (26.83) presented with fever, 33 (40.24%) presented with respiratory symptoms (p 0.029). There was a contact exposure in 3 (12.00%) and travel history in 8 (32.00%) of patients in the dead group while 13 (15.85%) had contact exposure and 9 (10.98%) had travel history among the alive group (p 0.042). All patients in the dead group were admitted in the hospital 25 (100.00%) and among these, 14 (56.00%) were admitted in ICU with a median 11 (6–16.5) number of days while 24 (29.27%) alive patients were admitted to hospital and only 4 (4.88%) admitted in ICU (p <0.001). At discharge or death, 4 (16.00%) dead patients were COVID positive, and 30 (36.59) alive patients were positive (p 0.008) (Table 3).

Table 1. Baseline and clinical characteristics of patients with hematological malignancies and COVID-19 stratified on the outcome (n = 107).

Characteristic Outcome n (%) P-value
Dead [25 (23.36%)] Alive [82 (76.64%)]
Age (years) 0.027
10–30 7 (28.00) 34 (41.46)
31–50 6 (24.00) 31 (37.80)
>50 12 (48.00) 17 (20.73)
Sex 0.566
Male 18 (72.00) 54 (68.85)
Female 7 (28.00) 28 (34.15)
Hospital 0.012
AKUH 8 (32.00) 9 (10.98)
SKMCH 6 (24.00) 48 (58.54)
Shifa Hospital 6 (24.00) 16 (19.51)
AFBMTC 5 (20.00) 7 (8.54)
HLH 0 (0.00) 2 (2.44)
Co-morbidities 0.021
None 8 (32.00) 50 (60.98)
HTN 8 (32.00) 8 (9.76)
Diabetes 2 (8.00) 7 (8.54)
Other 7 (28.00) 17 (20.73)
Malignancy 0.222
ALL 3 (12.00) 11 (13.41)
AML 7 (28.00) 6 (7.32)
CML 1 (4.00) 4 (4.88)
CLL 2 (8.00) 5 (6.10)
Hodgkins 2 (8.00) 17 (20.73)
B- cell lymphoma 4 (16.00) 21 (25.61)
T- cell lymphoma 1 (4.00) 3 (3.66)
Others 5 (20.00) 15 (18.29)
Open in a new tab

Table 2. Treatment and management of patients with hematological malignancies and COVID-19 stratified on outcome (n = 107).

Characteristic Outcome P-value
Dead [25 (23.36%)] Alive [82 (76.64%)]
Active treatment 0.020
Yes 21 (84.00) 48 (58.54)
No 4 (16.00) 34 (41.46)
Treatment 0.797
Chemoimmunotherapy 5 (23.81) 13 (27.66)
IV chemotherapy 15 (71.43) 29 (61.70)
TKI 1 (4.76) 4 (8.51)
Radiation 0 (0.00) 1 (2.13)
Chemo regimen 0.551
R-CHOP 2 (9.52) 7 (17.07)
R- Bendamustine 0 (0.00) 2 (4.88)
R-ICE 1 (4.76) 2 (4.88)
R-CEOP 0 (0.00) 1 (2.44)
R-EPOCH 1 (4.76) 1 (2.44)
Rituximab 1 (4.76) 0 (0.00)
CVP 0 (0.00) 1 (2.44)
Idarubicin + cytarabine 5 (23.81) 5 (12.20)
BFM protocol 1 (4.76) 3 (7.32)
HyperCVAD 4 (19.05) 5 (12.20)
ABVD 3 (14.29) 7 (17.07)
Bendamustine 0 (0.00) 2 (4.88)
VRD 3 (14.29) 1 (2.33)
Cyclophoshamide +bortezomib 0 (0.00) 2 (4.88)
Lenalodomide + carfilzomib 0 (0.00) 2 (4.88)
Open in a new tab

Table 3. COVID-19 exposure and status at death/discharge among hematological malignancies patients stratified on outcome (n = 107).

Characteristic Outcome P-value
Dead [25 (23.36%)] Alive [82 (76.64%)]
Presenting complaint 0.029
Fever 13 (52.00) 22 (26.83)
Respiratory symptoms 11 (44.00) 33 (40.24)
GI symptoms 1 (4.00) 4 (4.88)
Other 0 (0.00) 5 (6.10)
Asymptomatic 0 (0.00) 18 (21.95)
COVID-19 exposure 0.042
No 14 (56.00) 60 (73.17)
Contact exposure 3 (12.00) 13 (15.85)
Travel 8 (32.00) 9 (10.98)
Hospital admission <0.001
No 0 (0.00) 58 (70.73)
Yes 25 (100.00) 24 (29.27)
In hospital stay <0.001
No admission 0 (0.00) 58 (70.73)
Ward 5 (20.00) 16 (19.51)
SCU 6 (24.00) 4 (4.88)
ICU 14 (56.00) 4 (4.88)
If yes, Number of days 0.003*
(Median, IQR) 11 (6–16.5) 0 (0–4)
Recovered & discharged <0.001
No 25 (0.00) 2 (2.44)
Yes 0 (0.00) 35 (42.68)
Home isolation 0 (0.00) 45 (54.88)
COVID status at death/discharge 0.008
Not done 9 (36.00) 37 (45.12)
Negative 12 (48.00) 15 (18.29)
Positive 4 (16.00) 30 (36.59)
Open in a new tab

Overall survival and multivariable regression

The median overall survival among patients with hematological malignancies and COVID-19 positive was 33 (IQR 15–60) days (Fig 1). Upon applying multivariable Cox-proportional hazard regression, age (categorical), malignancy treatment, COVID-19 exposure, and COVID-19 status at death or discharge were significant (Table 4). The hazard ratio of survival or death in patients with hematological malignancies and COVID-19 positive in the age group 10–30 years was 1.81 times (CI: 1.40–2.72) and 1.22 times among age group 31–50 years (CI: 1.14–2.00) compared to age greater than 50 years (p 0.019). The hazard ratio of survival or death in patients with hematological malignancies and COVID-19 positive in patients receiving IV chemotherapy was 1.51 (CI: 1.26–2.47) times and 1.46 times who received chemoimmunotherapy (CI: 1.30–2.39) compared to those who received TKI (p 0.031). Among those who had contact exposure, the hazard of survival or death in patients with hematological malignancies and COVID-19 positive was 2.18 (CI: 1.90–4.44) times and 3.10 (CI: 2.73–4.60) times in patients with travel history compared to no exposure history (p 0.001). Moreover, the hazards were higher in patients who did not test for COVID or were positive at discharge or death 2.28 (CI: 1.43–5.63) and 3.41 (CI: 2.12–6.38) compared to those who were negative at discharge or death (p 0.001).

Fig 1. Graph representing overall survival in patients with hematological malignancies and COVID-19.

Fig 1

Open in a new tab

Table 4. Univariate and multivariable Cox-proportional hazard model reporting crude and adjusted ratios (n = 107).

Characteristic Crude HR (95% CI) p-value Adjusted HR (95% CI) p-value
Age (years)
>50 1 1
10–30 1.91 (1.84–2.37) 0.081* 1.81 (1.40–2.72) 0.019
31–50 1.17 (1.03–1.56) 1.22 (1.14–2.00)
Sex
Female 1 0.107* - -
Male 1.84 (1.38–3.05)
Active treatment
Yes 1 0.596 - -
No 1.19 (0.61–2.33)
Treatment
TKI 1 1
IV chemotherapy 1.19 (1.05–2.85) 0.084* 1.51 (1.26–2.47) 0.031
Chemoimmunotherapy 1.36 (1.10–3.50) 1.46 (1.30–2.69)
COVID-19 exposure
No 1 1
Contact exposure 1.49 (1.19–3.17) 0.058* 2.18 (1.90–4.44) 0.001
Travel 1.77 (1.61–5.12) 3.10 (2.73–4.60)
Hospital admission
No 1
Yes 1.16 (0.62–2.20) 0.628 - -
COVID status at death/discharge
Negative 1 1
Not done 1.80 (1.49–2.38) 0.024* 2.28 (1.43–5.63) 0.001
Positive 1.88 (1.58–4.16) 3.41 (2.12–6.38)
Open in a new tab

Discussion

Worldwide, healthcare systems are in an uphill task of dealing with the COVID-19 pandemic, a situation that is going to remain a challenge to all clinicians. The incidence of COVID-19 and outcomes in cancer patients is a topic of great interest. It is evident now that the COVID-19 will be a global health care issue for the foreseeable future, and it is imperative that clinicians understand the complexity of presentations and outcomes of patients with concomitant health issues that make them vulnerable to severe complications. Our study has mainly focused on outcomes of COVID-19 with hematological malignancies in a resource-constrained environment, and it’s the first multicenter analysis from Pakistan.

American Society for Hematology (ASH) Research Collaborative COVID-19 Registry analysis states that patients with hematologic malignancies have higher mortality resulting from COVID-19 than in the general population. They reported an overall mortality of 28%, increasing to 42% in patients with moderate to severe infection [15–17]. However, in the general population, it ranges from 9–29.6%. In the white Hispanic group, the mortality was less than 10%, while in Black and Hispanic groups, it was less than 30% in the general population [18]. Recently published study from Italy stated mortality of 37% patients with hematological malignancy and COVID-19, with higher risk amongst those with older age, progressive disease, or severe infection [19, 20]. Another multicenter study, analyzing outcomes in cancer patients from China reported mortality of 20%, with 41% mortality in the 22 patients with hematologic malignancies [21]. UK Myeloma Forum published their results of 75 patients with COVID-19 and multiple myeloma, with mortality of 55% [22, 23]. In our study, the overall mortality mirrors the data of these studies with an overall mortality of 23% and increasing to approximately 51% in the hospitalized patients and 86% in ICU patients. 50% of deaths were seen in patients younger than 50 years. This is most likely due to the fact that approximately 70% of our patients were in that age group. Therefore, this is likely over-represented. It was interesting to note the relatively low numbers of patients of older age admitted to the hospital in our cohort. It could be hypothesized that treatment was deferred for the older patients with multiple co-morbidities in the initial months of the pandemic if they had a relatively stable clinical course. However, it would be interesting to study the outcomes of patients who had their treatment deferred.

Several other findings from our cohort are noteworthy. We analyzed the demographics of COVID-19 patients with hematological malignancy and explored the effect of cytotoxic chemotherapy and various chemoimmunotherapy and targeted treatments on the trajectory of COVID-19. The incidence of COVID-19 was found to be more frequent in acute leukemias (29%), followed by non-Hodgkin’s lymphoma (27%) and Hodgkin’s lymphoma (18%) [24]. Furthermore, an increase in mortality has been reported in myeloid malignancies (MDS/AML/MPN) than lymphoid neoplasms (NHL/CLL/ALL/MM/HL) (43% vs. 35%) [25, 26], which is similar to that seen in our study population. The majority of our study patients were on active treatment and reported a mortality rate of 19.6%, in contrast to 10% among patients on surveillance. Interestingly a higher mortality rate (14%) was seen in patients receiving chemotherapy alone compared to a 4.6% receiving chemoimmunotherapy.

The most common COVID-19–specific therapies in our dataset were symptomatic treatment with steroids and anticoagulation, tocilizumab (6.5%), remdesivir (2.8%), hydroxychloroquine (3.7%). The use of tocilizumab and remdesivir in our cohort as low compared to other studies [10]. One reason is that our data collection started in the early days of the pandemic when these drugs were not used regularly. Additionally, the availability of the drugs was sparse until the mid of 2020. Remdisivir was given emergency use authorization in May 2020 and gained full FDA approval in October 2020. It only then has this drug become widely available for use.

Morbidity rates from COVID-19 in patients with cancer admitted to the hospital are high, particularly in older patients and those with hematological malignancies. But not all cancer patients are affected equally. These findings allow clinicians to risk-stratify their patients; whether symptomatic or not, and make decisions on social isolation and shielding at appropriate levels. Our data and many other studies demonstrate that patients with hematological malignancies, particularly acute leukemias, are at high risk for severe COVID-19 infection and mortality. Therefore, preemptive testing, early recognition of infections, and prompt management at a facility with expertise to manage complications are paramount. In addition, protective measures such as universal masks, social distancing, and shielding this susceptible population from COVID-19 exposure are mandatory. Many sites have implemented telemedicine to on-site physical distancing, and these practices should continue if COVID-19 prevalence remains high.

Our study has some limitations. Our analyses are based on patients with hematological malignancy who sought help from centers receiving their treatment. Therefore, this cohort did not capture the outcomes of patients who presented for management at a different hospital. This is particularly true for patients who live in cities or towns and most likely obtained treatment closer to home. Also, we likely missed patients on long-term follow-up who approached their local general physician (GP) or hospital. We, too, were unable to capture asymptomatic patients and found to have COVID-19 positive on screening. In addition, patients on hospice care were not reported or included in this study. Therefore, it is impossible to accurately quantify the burden of infection in patients with hematological malignancy.

Nonetheless, this dataset provides a glimpse of outcomes of patients who presented to a tertiary care hospital in Pakistan where both states of art management for covid infection and the primary malignancy was available. The majority of our patients were on active treatment, and these results help prognosticate; patients who require intensive care carry a very grim prognosis. Data such as ours are especially important in formulating country/region region-specific guidelines regarding the management of covid infections in a specific subset of patients. This is important in guiding management decisions when resources are limited and medical care is not covered by private insurance.

The expertise in managing COVID-19 infection has evolved over the last year. Early use of dexamethasone, remdesivir, and anticoagulation has improved outcomes.

Conclusion

In summary, this study of patients with hematological malignancy and COVID-19 accentuates several significant considerations for clinical care and emphasizes the urgent need for more data. Longer-term follow-up and larger sample sizes are needed to understand the effect of SARS-CoV-2 on outcomes in patients with hematological malignancy.

Supporting information

S1 Data

(XLSX)

Click here for additional data file. (37.9KB, xlsx)

Abbreviations

ASH

American Society for Hematology

CI

Confidence Interval

GP

General Physician

HR

Hazard Ratio

ICU

Intensive Care Unit

NHL

Non-Hodgkin’s Lymphoma

RT-PCR

Real Time Polymerase Chain Reaction

UK

United Kingdom

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

The authors received no specific funding for this work.

References

  • 1.Moujaess E, Kourie HR, Ghosn M. Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence. Critical reviews in oncology/hematology. 2020;150:102972. doi: 10.1016/j.critrevonc.2020.102972 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. New England journal of medicine. 2020. doi: 10.1056/NEJMoa2001316 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Ong SWX, Tan YK, Chia PY, Lee TH, Ng OT, Wong MSY, et al. Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. Jama. 2020;323(16):1610–2. doi: 10.1001/jama.2020.3227 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Waris A, Atta U, Ali M, Asmat A, Baset A. COVID-19 outbreak: current scenario of Pakistan. New Microbes and New Infections. 2020;35:100681. doi: 10.1016/j.nmni.2020.100681 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Jiang A-M, Shi X, Liu N, Gao H, Ren M-D, Zheng X-Q, et al. Nosocomial infections due to multidrug-resistant bacteria in cancer patients: a six-year retrospective study of an oncology Center in Western China. BMC Infectious Diseases. 2020;20(1):1–12. doi: 10.1186/s12879-020-05181-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Lièvre A, Bouché O, Aparicio T, Michel P, Pontchaillou C, Reims C, et al. Risque et gravité du COVID-19 chez les patients atteints de cancer digestif. [Google Scholar]
  • 7.Cao Y, Li Q, Chen J, Guo X, Miao C, Yang H, et al. Hospital emergency management plan during the COVID‐19 epidemic. Academic Emergency Medicine. 2020;27(4):309–11. doi: 10.1111/acem.13951 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Oh WK. COVID-19 infection in cancer patients: early observations and unanswered questions. Annals of Oncology. 2020;31(7):838–9. doi: 10.1016/j.annonc.2020.03.297 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Fontana L, Strasfeld L. Respiratory virus infections of the stem cell transplant recipient and the hematologic malignancy patient. Infectious Disease Clinics. 2019;33(2):523–44. doi: 10.1016/j.idc.2019.02.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Moataz S, Abd El Azim M, AbdelRaouf A, editors. Automated fish signals fusion detection for chronic myeloid leukemia diagnosis. 2016 26th International Conference on Computer Theory and Applications (ICCTA); 2016: IEEE.
  • 11.Djamilla A. TOWARDS AN INTELLIGENT APPROACH FOR THE DETECTION AND CLASSIFICATION OF CANCER OF THE LYMPHATIC SYSTEM: Universite laarbi tebessi tebessa; 2021. [Google Scholar]
  • 12.Giannakoulas N, Ntanasis-Stathopoulos I, Terpos E. The role of marrow microenvironment in the growth and development of malignant plasma cells in multiple myeloma. International Journal of Molecular Sciences. 2021;22(9):4462. doi: 10.3390/ijms22094462 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Mahmood M, Khan MF, Hasrat MN, Richwagen N. Transmission frequency of COVID-19 through pre-symptomatic and asymptomatic patients in AJK: a report of 201 cases. Virology Journal. 2021;18(1):1–8. doi: 10.1186/s12985-020-01472-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Zheng C, Wang J, Guo H, Lu Z, Ma Y, Zhu Y, et al. Risk-adapted treatment strategy for COVID-19 patients. International Journal of Infectious Diseases. 2020;94:74–7. doi: 10.1016/j.ijid.2020.03.047 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Wood WA, Neuberg DS, Thompson JC, Tallman MS, Sekeres MA, Sehn LH, et al. Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. Blood advances. 2020;4(23):5966–75. doi: 10.1182/bloodadvances.2020003170 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.ElGohary GM, Hashmi S, Styczynski J, Kharfan-Dabaja MA, Alblooshi RM, de la Cámara R, et al. The risk and prognosis of COVID-19 infection in cancer patients: A systematic review and meta-analysis. Hematology/oncology and stem cell therapy. 2020. doi: 10.1016/j.hemonc.2020.07.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Salunke AA, Nandy K, Pathak SK, Shah J, Kamani M, Kottakota V, et al. Impact of COVID-19 in cancer patients on severity of disease and fatal outcomes: a systematic review and meta-analysis. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020;14(5):1431–7. doi: 10.1016/j.dsx.2020.07.037 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and mortality among black patients and white patients with Covid-19. New England Journal of Medicine. 2020;382(26):2534–43. doi: 10.1056/NEJMsa2011686 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Mangone L, Gioia F, Mancuso P, Bisceglia I, Ottone M, Viventini M. COVID-19 patients and cancer in northern Italy. medRxiv. 2020:2020.11. 18.20233833. [Google Scholar]
  • 20.Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. The Lancet Haematology. 2020;7(10):e737–e45. doi: 10.1016/S2352-3026(20)30251-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Yang K, Sheng Y, Huang C, Jin Y, Xiong N, Jiang K, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. The Lancet Oncology. 2020;21(7):904–13. doi: 10.1016/S1470-2045(20)30310-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Cook G, John A, Pratt G, Popat R, Ramasamy K, Kaiser M, et al. Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy. British journal of haematology. 2020. doi: 10.1111/bjh.16874 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Wang B, Van Oekelen O, Mouhieddine TH, Del Valle DM, Richter J, Cho HJ, et al. A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. Journal of hematology & oncology. 2020;13(1):1–12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, et al. COVID-19 in persons with haematological cancers. Leukemia. 2020;34(6):1637–45. doi: 10.1038/s41375-020-0836-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Bonuomo V, Ferrarini I, Dell’Eva M, Sbisà E, Krampera M, Visco C. COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review. World Journal of Virology. 2021;10(6):312. doi: 10.5501/wjv.v10.i6.312 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer discovery. 2020;10(7):935–41. doi: 10.1158/2159-8290.CD-20-0516 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Sinan Kardeş

27 Dec 2021

PONE-D-21-33433Outcomes of COVID‐19 infection in patients with hematological malignancies​- A multicenter analysis from PakistanPLOS ONE

Dear Dr. Zaki,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Feb 10 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Sinan Kardeş, M.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please amend your current ethics statement to address the following concerns:

a) Did participants provide their written or verbal informed consent to participate in this study?

b) If consent was verbal, please explain i) why written consent was not obtained, ii) how you documented participant consent, and iii) whether the ethics committees/IRB approved this consent procedure.

3. Thank you for stating the following financial disclosure:

“No Funding received”

At this time, please address the following queries:

a)        Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

b)        State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

c)        If any authors received a salary from any of your funders, please state which authors and which funders.

d)        If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf

4. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

5. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: No

Reviewer #2: Partly

Reviewer #3: Partly

Reviewer #4: Partly

Reviewer #5: Partly

Reviewer #6: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: No

Reviewer #3: No

Reviewer #4: No

Reviewer #5: No

Reviewer #6: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #4: Yes

Reviewer #5: Yes

Reviewer #6: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

Reviewer #4: Yes

Reviewer #5: Yes

Reviewer #6: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors investigated the outcome of patients with hematological malignancies and Covid-19 infection in a multicenter retrospective cohort in Pakistan. I agree with the authors, that more research in the management of patients with severe immune-suppression and Covid-19 infection is urgently needed.

The collected data in this study are scarce and do not allow any new conclusion.

Unfortunately, this study does not provide any new insights in the field of Covid-19 infection in patients with hematological malignancies.

Reviewer #2: The current study describes 107 patients with COVID-19 and HM retrospectively collected from Pakistan (multicenter). I suggest the following changes to the manuscript:

- Needs extensive English editing.

- What is the rationale for not starting the inclusion criteria from the day of the epidemic start and choosing almost a year after this to start?

- Include the methodology (test details) of the COVID-19 diagnosis.

- The methodology section lacks important details (definitions [disease, variables, outcomes, severity classifications] and detail the statistical analysis.

- Add details of COVID-19 severity and severity classification.

- I suggest including a univariable and a multivariable analysis on the mortality and including important predictors in these analyses.

Reviewer #3: In the manuscript, PONE-D-21-33433, Zaki et al reported the COVID-19 infection outcomes of 107 patients with history of hematological malignancies that were presented at the Oncology Department of 5 tertiary care hospitals in Pakistan from February 2020 to August 2020. The authors summarized the overall clinical outcome, the patient characteristics, clinical presentations, treatments administered, and mortality rate stratified by age, type of malignancy and oncological treatment status for COVID19 in patients with hematological malignancy.

Specific concerns:

1. The authors concluded that their data supports the emerging consensus that patients with hematologic malignancies experience significant morbidity and mortality resulting from COVID-19 infection. However, there is no matched control cases in this study to compare with.

2. No statistical significance (P value) was assessed in the mortality rate analyses.

3. The calculation of mortality rate in Table 2 is wrong, which is the reason why the mortality rate in each group is lower than the overall mortality rate of the study cohort (28%). For example, when stratified for age, the authors said the mortality rate was 7.4%, 5.6% and 10.2% in the age groups 10-30 years, 31-50 years, and 51-70 years respectively. However, the true death rate should be 19.5% (8/41), 17.6 (6/34), and 37.9% (11/29), respectively.

4. Table 1 should be divided into multiple tables.

5. It might be better to present the data in Table 2 by one or more figures.

6. There are sporadic grammar errors throughout the manuscript.

Reviewer #4: Peer-review report

Title: “Outcomes of COVID‐19 infection in patients with hematological malignancies- A multicenter analysis from Pakistan”

Manuscript number: PONE-D-21-33433

Reviewer comment

- Thank you for inviting me to review this paper. I congratulate the authors for writing this research article. Based on their study, the authors describe the outcome of COVID-19 infection in patients with hematological malignancy. However, the document needs revision in the methodology and analysis section before considering the paper for publication.

Abstract

- Please expand the term COVID-19 and SARS-CoV-2

- In the method part, explain how the data is and analyzed and presented

- Replace …‘from February 2020 to August 2020’ with … from February to August 2020’.

- Please spell out numbers when they occur at the beginning of a sentence.

- The authors said that mortality rate is high in patients aged 50 and above without putting any statistical indicator (e.g. p-value). Accordingly, the information seems invalid.

- The conclusion of the study support the knowledge in the existing literature, but it seems relevant to add recommendation. //

Introduction

-explained fairly.

Method

Needs major revision considering the following points

- Clear description of the study setting, study populations, eligibility criteria (inclusion and exclusion criteria), data collection procedure, operational definition (if applicable), and ethical approval of the study (even a little is stated in the declaration section).

- In the statistical analysis part, why the authors preferred to use median over mean? Do the authors check the distribution of the data?

- Similarly, the chi-square test is performed. However, it is unclear where they put the report of this test in the result part.

- With the existing data on your hand, you can consider identifying the factor (s) associated with the COVID-19 outcome (optional).

Result

-Revise based on previous comment on the analysis part. You have to put the chi-square (optional) and the p-value in the stratification of mortality table.

Discussion

-Be consistent on the use of the word COVID-19. You have written as covid 19, COVID-19,...

-Expand the term ASH

- At the end of the discussion part please give a separate sub-heading and label as ‘conclusion’. In this part you can put your conclusion and recommendation (s).

- Revise the lists of abbreviation

Reviewer #5: In this study, Zaki et al, carried out a multicenter, retrospective, cohort study including 107 patients (aged ≥14 years) with diagnosis of hematological malignancy admitted to 5 tertiary care hospitals with laboratory-confirmed and symptomatic COVID-19.

As the authors rightly point out, the value of the study lies in being the first multicenter analysis from Pakistan and aimed at investigating outcome of patients with hematological malignancies and COVID-19 in a context with limited health care resources.

The outcomes in COVID- 19 cancer patients is a topic of great interest, and for this reason, a deeper characterization of the study population is recommended. In particular, the author should specify:

- the duration of follow-up

- the criteria used to define the severity of COVID-19 at admission

- patients with progressive disease, remission or in active therapy

Although in this study, the overall mortality mirrors data from studies carried out in other countries, suggesting a high risk for severe COVID-19 infection and mortality also in these patients, the author should discuss results comparing data with:

- mortality estimates for COVID-19 in the general population, possibly according to sex and stratified for age

- mortality estimates for pre-covid cohort with hematological malignancies, possibly stratified according to sex, age, type of hematological malignancy.

In order to make data analysis clearer to readers, characteristics of the study population should be reported in a table, with information on age/age groups, sex, comorbidities, type of hematological malignancy, disease status and therapy, COVID-19 severity, referred for all patients, survivors and non-survivors. And the results should be discussed accordingly. In particular, the features of the cohort study can be compared according to COVID-19 severity and outcome

Although the sample size makes this study not sufficiently robust to assess events and risk factors that can predict death in this clinical setting, a deeper statistical analysis evaluating association with overall survival of variable such as age, sex, comorbidity, type and status of neoplasia, etc., would help to objectively characterize these patients

Reviewer #6: The article captures data from the real world but has certain limitations, some of which have been highlighted. The comparative mortality and hospitalization statistics in the general population without hematological malignancies should be mentioned for the reader to make a fair comparison. The English should be brushed up. Have edited some of the errors in the attached pdf, but there are more.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: Yes: Zhijun Duan

Reviewer #4: No

Reviewer #5: No

Reviewer #6: Yes: Prantar Chakrabarti

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: PONE-D-21-33433_reviewer.pdf

Click here for additional data file. (769.4KB, pdf)
PLoS One. 2022 Apr 21;17(4):e0267139. doi: 10.1371/journal.pone.0267139.r002

Author response to Decision Letter 0

16 Feb 2022

Response to comments

Reviewer #1: The authors investigated the outcome of patients with hematological malignancies and Covid-19 infection in a multicenter retrospective cohort in Pakistan. I agree with the authors, that more research in the management of patients with severe immune-suppression and Covid-19 infection is urgently needed.

The collected data in this study are scarce and do not allow any new conclusion.

Unfortunately, this study does not provide any new insights in the field of Covid-19 infection in patients with hematological malignancies.

Response: This is a first ever multicenter local study conducted in Pakistan, we are presenting the data that we have collected from different settings in Pakistan which represents the local population, and it is highly generalizable to the Cancer patients with COVID-19. The findings may not be new but significant for the country and reflects the patient’s outcomes in an LMIC.

Reviewer #2: The current study describes 107 patients with COVID-19 and HM retrospectively collected from Pakistan (multicenter). I suggest the following changes to the manuscript:

- Needs extensive English editing.

Response: We have made changes and corrected English errors. See track changes.

- What is the rationale for not starting the inclusion criteria from the day of the epidemic start and choosing almost a year after this to start?

Response: We have thought of this study since very beginning but as it is a multicenter study it took some time to get the permissions from Departmental and Institutional review boards for data collection and analysis.

- Include the methodology (test details) of the COVID-19 diagnosis.

Response: tested positive for COVID-19 by RT-PCR (page # 6 line # 16)

- The methodology section lacks important details (definitions [disease, variables, outcomes, severity classifications] and detail the statistical analysis.

Response: Added (page # 7 line # 18-23 page # 8 line # 1-25)

Operational definition

Disease

Leukemia is cancer of the body's blood-forming tissues, including the bone marrow and the lymphatic system

Lymphoma is a cancer of the lymphatic system, which is part of the body's germ-fighting network. The lymphatic system includes the lymph nodes (lymph glands), spleen, thymus gland and bone marrow.

Multiple myeloma is a cancer of plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system.

Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow become abnormal. This leads to low numbers of one or more types of blood cells.

- Add details of COVID-19 severity and severity classification.

Response:

Clinical classification of suspected or confirmed COVID-19 patients in Pakistan

Asymptomatic SARS CoV-2 infection but with no symptoms. Some asymptomatic patients may be pre-symptomatic if tested early (e.g. as part of contact tracing).

Non-Severe Oxygen saturation of 94% or greater and respiratory rate of less than 25 breaths/minute.

Severe Oxygen saturation < 94 % and respiratory rate greater than 25 breath/minute.

Oxygen saturation is maintained by nasal cannulation or simple facemask, no need for non-invasive or invasive mechanical ventilation.

Critical Respiratory compromise severe enough requiring invasive and non- invasive mechanical ventilation.

Variables

Age, Sex, Hospital, Co-morbidities, Hematological malignancy, treatment, chemotherapy, COVID-19 exposure, presenting complaint, hospital admission, COVID-19 status at death or discharge were the covariates.

Statistical analysis

The data was entered and analyzed by using STATA version 16. Calculated medians for all continuous variables and frequencies with percentages for categorical variables. Chi-square test was performed to check the association between the covariates and mortality. For survival analysis multivariable Cox-regression hazard regression model was applied and Kaplan Meir survival curve was used to check the overall survival. P-value ≤0.05 was considered significant.

I suggest including a univariable and a multivariable analysis on the mortality and including important predictors in these analyses.

Response: Univariable and a multivariable analysis on the mortality is done see page # 22 table 4

Reviewer #3: In the manuscript, PONE-D-21-33433, Zaki et al reported the COVID-19 infection outcomes of 107 patients with history of hematological malignancies that were presented at the Oncology Department of 5 tertiary care hospitals in Pakistan from February 2020 to August 2020. The authors summarized the overall clinical outcome, the patient characteristics, clinical presentations, treatments administered, and mortality rate stratified by age, type of malignancy and oncological treatment status for COVID19 in patients with hematological malignancy.

1.The authors concluded that their data supports the emerging consensus that patients with hematologic malignancies experience significant morbidity and mortality resulting from COVID-19 infection. However, there is no matched control cases in this study to compare with.

Response: Thanks for the comment. This is a retrospective observational study where we just have taken the data of patients with hematological malignancy and were COVID-19 positive. We can do matched case control study in future for comparison.

2. No statistical significance (P value) was assessed in the mortality rate analyses.

Response: Tables are revised. P-value added in the tables by applying chi-square.

3. The calculation of mortality rate in Table 2 is wrong, which is the reason why the mortality rate in each group is lower than the overall mortality rate of the study cohort (28%). For example, when stratified for age, the authors said the mortality rate was 7.4%, 5.6% and 10.2% in the age groups 10-30 years, 31-50 years, and 51-70 years respectively. However, the true death rate should be 19.5% (8/41), 17.6 (6/34), and 37.9% (11/29), respectively.

Response: The analysis tables are changed to basic tables with chi-square & multivariable survival regression and calculated overall survival.

4. Table 1 should be divided into multiple tables.

Response: Table 1 is changed to baseline characteristics and is stratified on outcome (alive/ dead) and p-values taken out with chi-square.

5. It might be better to present the data in Table 2 by one or more figures.

Response: The table 2 is changed to treatment and management of patient stratified on outcome (alive/ dead) and p-values taken out with chi-square.

6. There are sporadic grammar errors throughout the manuscript.

Response: Grammatical errors rectified.

Reviewer #4: Peer-review report

Title: “Outcomes of COVID‐19 infection in patients with hematological malignancies- A multicenter analysis from Pakistan”

Manuscript number: PONE-D-21-33433

Reviewer comment

- Thank you for inviting me to review this paper. I congratulate the authors for writing this research article. Based on their study, the authors describe the outcome of COVID-19 infection in patients with hematological malignancy. However, the document needs revision in the methodology and analysis section before considering the paper for publication.

Abstract

- Please expand the term COVID-19 and SARS-CoV-2

Response: Explained with detail page #7

- In the method part, explain how the data is and analyzed and presented

Response: The data was entered and analyzed by using STATA version 16. Calculated medians for all skewed continuous variables. Normality of data was check through density plots. Frequencies with percentages for categorical variables. Chi-square test was performed to check the association between the covariates and mortality. For survival analysis multivariable Cox-regression hazard regression model was applied and Kaplan Meir survival curve was used to check the overall survival. P-value ≤0.05 was considered significant. Page # 8.

- Replace …‘from February 2020 to August 2020’ with … from February to August 2020’.

Response: changed from February to August 2020

- Please spell out numbers when they occur at the beginning of a sentence.

Response: Changed.

- The authors said that mortality rate is high in patients aged 50 and above without putting any statistical indicator (e.g. p-value). Accordingly, the information seems invalid.

Response: The results are changed completely. The baseline details and clinical details are stratified on outcome (alive/dead) and p-value are taken through chi-square. Moreover multivariable analysis was done using Cox-regression.

- The conclusion of the study support the knowledge in the existing literature, but it seems relevant to add recommendation. //

Introduction

-explained fairly.

Method

Needs major revision considering the following points

- Clear description of the study setting, study populations, eligibility criteria (inclusion and exclusion criteria), data collection procedure, operational definition (if applicable), and ethical approval of the study (even a little is stated in the declaration section).

Response: Data was collected using a standard Performa developed for this study. Demographic, clinical, treatment and laboratory data and serial samples for viral RNA detection were extracted from medical records of 107 patients. Patient with any known hematological malignancy who was positive for COVID-19 on RT-PCR was included in the study. Patients with a clinical or radiological diagnosis of COVID-19, without a positive RT-PCR test were not included in this analysis. Ethical approval was obtained from Ethical Review Committee of the Aga Khan University Hospital, Karachi, Pakistan. Data was retrospectively collected through chart review so there was no need of the informed written consent.

- In the statistical analysis part, why the authors preferred to use median over mean? Do the authors check the distribution of the data?

Response: Normality of data was check through density plots. For skewed data Median & IQR was calculated.

- Similarly, the chi-square test is performed. However, it is unclear where they put the report of this test in the result part.

Response: Chi-square test was performed to check the association between the covariates and mortality. P-values reported.

- With the existing data on your hand, you can consider identifying the factor (s) associated with the COVID-19 outcome (optional).

Response: Thanks for suggestion it can be done in a prospective study.

Result

-Revise based on previous comment on the analysis part. You have to put the chi-square (optional) and the p-value in the stratification of mortality table.

Response: Chi-square test was performed to check the association between the covariates and mortality. P-values reported.

Discussion

-Be consistent on the use of the word COVID-19. You have written as covid 19, COVID-19,...

Response: changed to COVID-19 in whole manuscript

-Expand the term ASH

Response: American Society for Hematology (ASH) page #24

- At the end of the discussion part please give a separate sub-heading and label as ‘conclusion’.

Response: Added a separate section

In this part you can put your conclusion and recommendation (s).

- Revise the lists of abbreviation

Response: Revised abbreviations

Reviewer #5: In this study, Zaki et al, carried out a multicenter, retrospective, cohort study including 107 patients (aged ≥14 years) with diagnosis of hematological malignancy admitted to 5 tertiary care hospitals with laboratory-confirmed and symptomatic COVID-19.

As the authors rightly point out, the value of the study lies in being the first multicenter analysis from Pakistan and aimed at investigating outcome of patients with hematological malignancies and COVID-19 in a context with limited health care resources.

The outcomes in COVID- 19 cancer patients is a topic of great interest, and for this reason, a deeper characterization of the study population is recommended. In particular, the author should specify:

- the duration of follow-up

Response: There was no follow-up as it’s a retrospective study. The suggestion is nice a prospective follow-up study can be done in future.

- the criteria used to define the severity of COVID-19 at admission

Response: patients with a history of histologically proven hematological malignancies that tested positive for COVID-19 by RT-PCR

- patients with progressive disease, remission or in active therapy

Patients with active therapy/ treatment are included (see table 2). Progressive disease or remission were not recorded.

Although in this study, the overall mortality mirrors data from studies carried out in other countries, suggesting a high risk for severe COVID-19 infection and mortality also in these patients, the author should discuss results comparing data with:

- mortality estimates for COVID-19 in the general population, possibly according to sex and stratified for age

Response: Mortality recorded in age groups & sex refer to table 1.

- mortality estimates for pre-covid cohort with hematological malignancies, possibly stratified according to sex, age, type of hematological malignancy.

Response: Results are revised characteristics such as age, gender, malignancy & others were check with outcome alive/dead and chi-square test was run to see the significance.

In order to make data analysis clearer to readers, characteristics of the study population should be reported in a table, with information on age/age groups, sex, comorbidities, type of hematological malignancy, disease status and therapy, COVID-19 severity, referred for all patients, survivors and non-survivors. And the results should be discussed accordingly. In particular, the features of the cohort study can be compared according to COVID-19 severity and outcome

Response: Results are revised characteristics such as age, gender, malignancy & others were check with outcome alive/dead and chi-square test was run to see the significance. Moreover multivariable analysis was performed using Cox-regression to see the survival by regressing all independent variables again outcome alive/dead.

Although the sample size makes this study not sufficiently robust to assess events and risk factors that can predict death in this clinical setting, a deeper statistical analysis evaluating association with overall survival of variable such as age, sex, comorbidity, type and status of neoplasia, etc., would help to objectively characterize these patients

Response: Multivariable analysis was performed using Cox-regression to see the survival by regressing all independent variables again outcome alive/dead.

Reviewer #6: The article captures data from the real world but has certain limitations, some of which have been highlighted. The comparative mortality and hospitalization statistics in the general population without hematological malignancies should be mentioned for the reader to make a fair comparison. The English should be brushed up. Have edited some of the errors in the attached pdf, but there are more.

Response: Grammatical editing has been done.

Attachment

Submitted filename: Response to multicenter outcomes comments.docx

Click here for additional data file. (26.4KB, docx)

Decision Letter 1

Sinan Kardeş

9 Mar 2022

PONE-D-21-33433R1Outcomes of COVID‐19 infection in patients with hematological malignancies​- A multicenter analysis from PakistanPLOS ONE

Dear Dr. Zaki,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Apr 23 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Sinan Kardeş, M.D.

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

Reviewer #3: All comments have been addressed

Reviewer #4: All comments have been addressed

Reviewer #5: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #3: Yes

Reviewer #4: Yes

Reviewer #5: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #3: Yes

Reviewer #4: Yes

Reviewer #5: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #3: Yes

Reviewer #4: Yes

Reviewer #5: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #3: No

Reviewer #4: No

Reviewer #5: No

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors of the manuscript "Outcomes of COVID‐19 infection in patients with hematological malignancies​- A multicenter analysis from Pakistan“ have partially addressed previous comments. The manuscript still needs intensive language editing.

Reviewer #3: The authors have addressed most of the concerns from the 1st-round review, and this reviewer is satisfied with the improved quality of the revised manuscript. However, the English language skill still needs to be improved.

Reviewer #4: Dear /sir, most of the comments given were addressed correctly. I have a few suggestions to improve the readability of this manuscript before publication is commenced. My concerns are:-

- Please expand the term COVID-19 and SARS-CoV-2 at the beginning of the abstract page 3 line 3

- Replace …‘from February 2020 to August 2020’ with … from February to August 2020’ page 3 line 11.

- The information included in the operational definition must be cited with appropriate literature/s.

- Authors should check for typos and grammatical errors throughout the manuscript which need to be edited after careful reading.

Reviewer #5: I sugest the authors to keep the first 3 paragraph of Baseline characteristics, taking care to integrate the information added in the revised version to avoid repetitions

The comparative mortality and hospitalization statistics in the general population should be mentioned for the reader to

make a fair comparison.

English should be improved

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #3: No

Reviewer #4: No

Reviewer #5: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Apr 21;17(4):e0267139. doi: 10.1371/journal.pone.0267139.r004

Author response to Decision Letter 1

17 Mar 2022

Reviewer #1: The authors of the manuscript "Outcomes of COVID‐19 infection in patients with hematological malignancies- A multicenter analysis from Pakistan“ have partially addressed previous comments. The manuscript still needs intensive language editing.

Response: Grammatical corrections are made, see track changes

Reviewer #3: The authors have addressed most of the concerns from the 1st-round review, and this reviewer is satisfied with the improved quality of the revised manuscript. However, the English language skill still needs to be improved.

Response: Grammatical corrections are made, see track changes

Reviewer #4: Dear /sir, most of the comments given were addressed correctly. I have a few suggestions to improve the readability of this manuscript before publication is commenced. My concerns are:-

- Please expand the term COVID-19 and SARS-CoV-2 at the beginning of the abstract page 3 line 3

Response: Changed to Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Coronavirus disease of 2019 (COVID-19) page #3 line #3-4

- Replace …‘from February 2020 to August 2020’ with … from February to August 2020’ page 3 line 11.

Response: Changed to February to August 2020

- The information included in the operational definition must be cited with appropriate literature/s.

Response: Cited all operational definitions

- Authors should check for typos and grammatical errors throughout the manuscript which need to be edited after careful reading.

Response: Grammatical corrections are made, see track changes

Reviewer #5: I suggest the authors to keep the first 3 paragraph of Baseline characteristics, taking care to integrate the information added in the revised version to avoid repetitions.

Response: Made two sections added first 3 paragraphs with their tables in baseline characteristics and rest in multivariable analysis.

The comparative mortality and hospitalization statistics in the general population should be mentioned for the reader to make a fair comparison.

Response: However, in the general population it range from 9-29.6%. In white Hispanic group the morality was less than 10% while in Black and Hispanic groups it was less than 30% in the general population. Page 18 line# 6-8

Attachment

Submitted filename: Response to reviewer comments multicenter.docx

Click here for additional data file. (14KB, docx)

Decision Letter 2

Sinan Kardeş

4 Apr 2022

Outcomes of COVID‐19 infection in patients with hematological malignancies​- A multicenter analysis from Pakistan

PONE-D-21-33433R2

Dear Dr. Zaki,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Sinan Kardeş, M.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #3: All comments have been addressed

Reviewer #4: All comments have been addressed

Reviewer #5: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #3: Yes

Reviewer #4: Yes

Reviewer #5: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #3: Yes

Reviewer #4: Yes

Reviewer #5: N/A

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #3: Yes

Reviewer #4: Yes

Reviewer #5: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #3: Yes

Reviewer #4: Yes

Reviewer #5: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #3: (No Response)

Reviewer #4: (No Response)

Reviewer #5: The authors of the manuscript "Outcomes of COVID‐19 infection in patients with hematological malignancies- A multicenter analysis from Pakistan“ have addressed previous comments.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #3: No

Reviewer #4: No

Reviewer #5: No

Acceptance letter

Sinan Kardeş

6 Apr 2022

PONE-D-21-33433R2

“Outcomes of COVID‐19 infection in patients with hematological malignancies​- A multicenter analysis from Pakistan”

Dear Dr. Zaki:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Sinan Kardeş

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Data

    (XLSX)

    Click here for additional data file. (37.9KB, xlsx)
    Attachment

    Submitted filename: PONE-D-21-33433_reviewer.pdf

    Click here for additional data file. (769.4KB, pdf)
    Attachment

    Submitted filename: Response to multicenter outcomes comments.docx

    Click here for additional data file. (26.4KB, docx)
    Attachment

    Submitted filename: Response to reviewer comments multicenter.docx

    Click here for additional data file. (14KB, docx)

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files.

    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES